Response to Comments
CTAF

PDF cover

Asthma: ICER’s Response to Public Comments

ICER’s responses to public comments received on the draft report Mepolizumab (Nucala®, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value-Based Price Benchmarks.

View

View All Materials on this Topic or Go Back to View More Materials